Publication of results from DFV890D12201 study: DFV890, a new oral NLRP3 inhibitor, tested for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function: Results from a randomised Phase 2 trial
Junge, Guido, Mehes, Beata, Meiser, Karin, Gatlik, Ewa, Sommer, Ulrike, Madurka, Ildiko, Rezende, Ederlon, Vishnevsky, Alexander, Soriano, Joan B, Gans, Stephanus J., Salazar Ore, Danilo Joel, Rendon, Adrian, Suppli Ulrik, Charlotte, Bhatnagar, Sushma, Krishnamurthy, Srikanth, Mc Harry, Kirsten, Welte, Tobias and Fernandez, Alberto Alfredo (2022) Publication of results from DFV890D12201 study: DFV890, a new oral NLRP3 inhibitor, tested for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function: Results from a randomised Phase 2 trial. DFV890, a new oral NLRP3 inhibitor, tested for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function: Results from a randomised Phase 2 trial. ISSN 1439-0973 (electronic), 0300-8126 (print)
Abstract
No abstract
Item Type: | Article |
---|---|
Date Deposited: | 13 Dec 2022 00:46 |
Last Modified: | 13 Dec 2022 00:46 |
URI: | https://oak.novartis.com/id/eprint/46588 |